Publications Archives - PDC Therapeutics

Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors.

Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors. ASCO 2025, Chicago Authors Ozturk Ates1, Gulsah Nomak2, Hakan Orer3, Recep Selim Şentürk4, Fevzi Altuntas1, Hamdi Sena Nomak5, Rana Sanyal2 Organizations 1Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Health Sciences University, Ankara, Turkey 2RS Research, Istanbul, Turkey 3Koc University, […]

RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models ESMO TAT 2023, Paris Authors G. Nomak1, M. Karacivi2, S. Kutlu Ozkaya2, U. Valeria3, B. Sumer Bolu2, T. Karatas2, C.V. Catapano3, H.S. Orer4, A. Sanyal5, R. Sanyal2 Affiliations 1Medical, RS Research, Istanbul, Turkey […]

Phase Ia/Ib study of RS-0139 a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer

Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC) ESMO 2022, Paris Authors H.S. Orer1, G. Nomak2, B.O. Oksuzoglu3, R.S. Senturk4, Y. Eralp5, F.P. Yumuk6, H.S. Nomak7, R. Sanyal8 Affiliations 1Medical Pharmacology, Koc University School of Medicine, Istanbul, Turkey 2Medical, […]